Trial in progress: Feasibility of CSF and plasma ctDNA in BRAF-altered glioma during treatment with plixorafenib. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback